Jason Gerberry Analyst PerformanceEquity Research at Bank of AmericaJason Gerberry is a stock analyst at Bank of America focused in the healthcare sector, covering 34 publicly traded companies. Over the past year, Jason Gerberry has issued 31 stock ratings, including buy, hold, and sell recommendations. While full access to Jason Gerberry's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jason Gerberry's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings138 Last 11 YearsBuy Recommendations69.12% 94 Buy RatingsCompanies Covered34 Unique Companies Ratings Distribution136RatingsDistribution of strong buy, buy, hold, and sell ratings by Jason Gerberry.RatingPercentageCount Strong Buy0.0%0 ratings Buy69.1%94 ratings Hold23.5%32 ratings Sell7.4%10 ratingsOut of 136 total stock ratings issued by Jason Gerberry at Bank of America, the majority (69.1%) have been Buy recommendations, followed by 23.5% Hold and 7.4% Sell.Best & Worst CallsBest Call0000.0%LQDAJun 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%BLPHJul 2015Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ76.5% of companies on NASDAQ26 companiesNYSE23.5% of companies on NYSE8 companiesJason Gerberry, an analyst at Bank of America, currently covers 34 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare33 companies97.1%Miscellaneous1 company2.9%Jason Gerberry of Bank of America specializes in stock coverage within the Healthcare sector, with additional focus on companies.Coverage IndustriesIndustryPercentagePHARMACEUTICALS20 companies58.8%BIOTECHNOLOGY13 companies38.2%Miscellaneous1 company2.9% Jason Gerberry's Ratings History at Bank of America Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsAPMDApnimed8/25/2026Initiated Coverage$25.63$41.00Buy$0.0000.00% ROIALVOAlvotech8/24/2026Initiated Coverage$4.43$7.00Buy$0.0000.00% ROILQDALiquidia8/13/2026Boost Price Target$78.79$92.00Neutral$0.0000.00% ROIPFEPfizer7/10/2026Lower Price Target$24.25$26.00Neutral$0.0000.00% ROILLYEli Lilly and Company7/10/2026Boost Price Target$1,183.80$1,334.00Buy$0.0000.00% ROIALKSAlkermes6/29/2026Reiterated Rating$55.08Underperform$0.0000.00% ROILQDALiquidia6/29/2026Reiterated Rating$78.17$79.00Neutral$0.0000.00% ROIAMPHAmphastar Pharmaceuticals6/29/2026Reiterated Rating$21.78$20.00Underperform$0.0000.00% ROIBHVNBiohaven6/29/2026Reiterated Rating$15.79$11.00Underperform$0.0000.00% ROIJAZZJazz Pharmaceuticals6/10/2026Boost Price Target$229.19$307.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. LLYEli Lilly and Company5/26/2026Boost Price Target$1,066.59$1,251.00Buy$0.0000.00% ROIIMVTImmunovant5/21/2026Boost Price Target$35.56$43.00Buy$0.0000.00% ROILLYEli Lilly and Company5/1/2026Lower Price Target$965.19$1,133.00Buy$0.0000.00% ROITEVATeva Pharmaceutical Industries4/9/2026Boost Price Target$30.77$42.00Buy$0.0000.00% ROIPFEPfizer4/9/2026Lower Price Target$27.39$26.00Neutral$0.0000.00% ROIIONSIonis Pharmaceuticals4/9/2026Boost Price Target$76.12$111.00Buy$0.0000.00% ROIALKSAlkermes4/9/2026Boost Price Target$34.90$36.00Neutral$0.0000.00% ROILLYEli Lilly and Company4/2/2026Boost Price Target$955.45$1,294.00Buy$0.0000.00% ROILENZLENZ Therapeutics3/25/2026Lower Price Target$9.03$29.00Buy$0.0000.00% ROIJAZZJazz Pharmaceuticals2/25/2026Boost Price Target$173.83$275.00Buy$0.0000.00% ROIHRMYHarmony Biosciences2/25/2026Lower Price Target$28.19$28.00Underperform$0.0000.00% ROIALKSAlkermes2/20/2026Boost Price Target$32.00$34.00Neutral$0.0000.00% ROIPFEPfizer12/15/2025Lower Price Target$25.86$28.00Neutral$0.0000.00% ROIARWRArrowhead Pharmaceuticals12/9/2025Boost Price Target$69.57$81.00Buy$0.0000.00% ROIIONSIonis Pharmaceuticals12/9/2025Boost Price Target$79.56$97.00Buy$0.0000.00% ROITEVATeva Pharmaceutical Industries12/9/2025Boost Price Target$28.60$32.00Buy$0.0000.00% ROIARWRArrowhead Pharmaceuticals12/1/2025Boost Price Target$55.43$62.00Buy$0.0000.00% ROIJAZZJazz Pharmaceuticals11/18/2025Boost Price Target$170.09$247.00Buy$0.0000.00% ROIOCSOculis11/13/2025Lower Price Target$19.25$29.00Buy$0.0000.00% ROIBHVNBiohaven11/5/2025Downgrade$8.10$10.00Neutral$0.0000.00% ROIIONSIonis Pharmaceuticals9/23/2025Boost Price Target$61.36$83.00Buy$0.0000.00% ROIAMPHAmphastar Pharmaceuticals8/26/2025Boost Price Target$30.54$32.00Neutral$00.0000.00% ROIIMVTImmunovant8/12/2025Lower Price Target$14.76$30.00Buy$00.0000.00% ROIBHVNBiohaven8/12/2025Lower Price Target$13.42$49.00Buy$00.0000.00% ROIAXSMAxsome Therapeutics8/5/2025Boost Price Target$102.86$176.00Buy$000.0000.00% ROIPROKProKidney6/30/2025Downgrade$0.67$1.00Underperform$0.0000.00% ROILQDALiquidia6/11/2025Lower Price Target$14.34$23.00Buy$00.0000.00% ROIEXELExelixis6/5/2025Boost Price Target$42.55$46.00Neutral$00.0000.00% ROITEVATeva Pharmaceutical Industries5/8/2025Boost Price Target$18.08$22.00Buy$00.0000.00% ROIPCVXVaxcyte4/1/2025Lower Price Target$36.81$137.00Buy$00.0000.00% ROIThey didn't warn anyone in 1971. This time someone is warning you. (Ad)On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.Request the free guide in 30 seconds and get positioned nowIMVTImmunovant3/20/2025Lower Price Target$18.88$33.00Buy$00.0000.00% ROITEVATeva Pharmaceutical Industries3/6/2025Lower Price Target$15.59$20.00Buy$00.0000.00% ROIVTRSViatris2/28/2025Lower Price Target$9.53$10.00Underperform$00.0000.00% ROIAXSMAxsome Therapeutics2/11/2025Boost Price Target$133.41$167.00Buy$000.0000.00% ROIIMVTImmunovant1/15/2025Lower Price Target$22.88$45.00Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftBMO Capital MarketsMizuho Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
